慢性鼻窦炎伴鼻息肉患者鼻息肉中的白细胞介素-17与健康对照的比较：一项系统综述

文献信息

中文摘要

引言： 慢性鼻窦炎伴鼻息肉（CRSwNP）是一种累及鼻腔鼻窦的炎症性疾病，显著影响生活质量。单克隆抗体的新型疗法为其治疗带来了范式转变。白细胞介素-17（IL-17）是已知的炎症通路介质，其在CRSwNP中的作用尚存争议。
目的： 评估CRSwNP患者鼻息肉中IL-17的存在情况，并与鼻黏膜健康的受试者进行比较。
数据综合： 我们按照系统综述和荟萃分析优先报告条目（PRISMA）声明开展了一项系统综述。文献检索在PubMed/MEDLINE、Google Scholar和Cochrane Library上进行。我们共纳入15项研究，涉及785例CRSwNP患者。在大多数纳入研究中，鼻息肉组织中的IL-17水平升高。
结论： 本研究表明，抗IL-17治疗可能有效控制CRSwNP。进一步的研究可评估其用于CRSwNP的安全性和有效性。

英文摘要

INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the sinonasal tract that significantly impacts quality of life. Novel therapies with monoclonal antibodies brought a paradigm shift to its treatment. Interleukin-17 (IL-17) is a known mediator of inflammatory pathways and its role in CRSwNP is debatable.
OBJECTIVES: To evaluate the presence of IL-17 in the nasal polyps of patients with CRSwNP compared with subjects with healthy nasal mucosa.
DATA SYNTHESIS: We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. The literature search was performed on the PubMed/MEDLINE, Google Scholar, and Cochrane Library. We identified 15 studies with a total of 785 patients with CRSwNP. The levels of IL-17 were increased in nasal polypoid tissue in most of the included studies.
CONCLUSION: The current study suggests that anti-IL-17 treatments might effectively control CRSwNP. Further studies could assess their safety and efficacy for CRSwNP.